These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38924865)

  • 21. Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN.
    Tafaghodi M; Khamesipour A; Jaafari MR
    Parasitol Res; 2011 May; 108(5):1265-73. PubMed ID: 21125294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of immune responses in guinea pigs by intranasal delivery with different nanoparticles-loaded FMDV DNA vaccine.
    Zheng H; Pan L; Lv J; Zhang Z; Wang Y; Hu W; Liu X; Zhou P; Wang Y; Zhang Y
    Microb Pathog; 2020 Feb; 142():104061. PubMed ID: 32061916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).
    Jayakumar A; Castilho TM; Park E; Goldsmith-Pestana K; Blackwell JM; McMahon-Pratt D
    PLoS Negl Trop Dis; 2011 Jun; 5(6):e1204. PubMed ID: 21695103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Itraconazole encapsulated PLGA-nanoparticles covered with mannose as potential candidates against leishmaniasis.
    Biswaro LS; Garcia MP; da Silva JR; Neira Fuentes LF; Vera A; Escobar P; Azevedo RB
    J Biomed Mater Res B Appl Biomater; 2019 Apr; 107(3):680-687. PubMed ID: 30091522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coinjection with TLR2 agonist Pam3CSK4 reduces the pathology of leishmanization in mice.
    Huang L; Hinchman M; Mendez S
    PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003546. PubMed ID: 25738770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice.
    Zhang WW; Matlashewski G
    Infect Immun; 2008 Aug; 76(8):3777-83. PubMed ID: 18474642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.
    Schaut RG; Grinnage-Pulley TL; Esch KJ; Toepp AJ; Duthie MS; Howard RF; Reed SG; Petersen CA
    Vaccine; 2016 Oct; 34(44):5225-5234. PubMed ID: 27665354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant effects of TLR agonist gardiquimod admixed with Leishmania vaccine in mice model of visceral leishmaniasis.
    Goyal DK; Keshav P; Kaur S
    Infect Genet Evol; 2021 Sep; 93():104947. PubMed ID: 34052416
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
    Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toll-like receptor 2 (TLR2) plays a role in controlling cutaneous leishmaniasis in vivo, but does not require activation by parasite lipophosphoglycan.
    Halliday A; Bates PA; Chance ML; Taylor MJ
    Parasit Vectors; 2016 Oct; 9(1):532. PubMed ID: 27716391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment.
    Lin W; Li C; Xu N; Watanabe M; Xue R; Xu A; Araki M; Sun R; Liu C; Nasu Y; Huang P
    Int J Nanomedicine; 2021; 16():2775-2787. PubMed ID: 33880023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Total Leishmania antigens with Poly(I:C) induce Th1 protective response.
    Sanchez MV; Eliçabe RJ; Di Genaro MS; Germanó MJ; Gea S; García Bustos MF; Salomón MC; Scodeller EA; Cargnelutti DE
    Parasite Immunol; 2017 Nov; 39(11):. PubMed ID: 28901553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of a new live recombinant vaccine against cutaneous leishmaniasis in BALB/c mice.
    Salari S; Sharifi I; Keyhani AR; Ghasemi Nejad Almani P
    Parasit Vectors; 2020 Aug; 13(1):415. PubMed ID: 32787908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis.
    Heravi Shargh V; Jaafari MR; Khamesipour A; Jalali SA; Firouzmand H; Abbasi A; Badiee A
    Parasitol Res; 2012 Jul; 111(1):105-14. PubMed ID: 22223037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cross-protective efficacy of Leishmania infantum LiHyD protein against tegumentary leishmaniasis caused by Leishmania major and Leishmania braziliensis species.
    Lage DP; Martins VT; Duarte MC; Costa LE; Tavares GSV; Ramos FF; Chávez-Fumagalli MA; Menezes-Souza D; Roatt BM; Tavares CAP; Coelho EAF
    Acta Trop; 2016 Jun; 158():220-230. PubMed ID: 26976272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral pentamidine-loaded poly(d,l-lactic-co-glycolic) acid nanoparticles: an alternative approach for leishmaniasis treatment.
    Valle IV; Machado ME; Araújo CDCB; da Cunha-Junior EF; da Silva Pacheco J; Torres-Santos EC; da Silva LCRP; Cabral LM; do Carmo FA; Sathler PC
    Nanotechnology; 2019 Nov; 30(45):455102. PubMed ID: 31365912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PLGA nanoparticles modified with a TNFα mimicking peptide, soluble Leishmania antigens and MPLA induce T cell priming in vitro via dendritic cell functional differentiation.
    Margaroni M; Agallou M; Kontonikola K; Karidi K; Kammona O; Kiparissides C; Gaitanaki C; Karagouni E
    Eur J Pharm Biopharm; 2016 Aug; 105():18-31. PubMed ID: 27235727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Multiepitope Peptide, rOmp22, Encapsulated in Chitosan-PLGA Nanoparticles as a Candidate Vaccine Against
    Du X; Xue J; Jiang M; Lin S; Huang Y; Deng K; Shu L; Xu H; Li Z; Yao J; Chen S; Shen Z; Feng G
    Int J Nanomedicine; 2021; 16():1819-1836. PubMed ID: 33707942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.
    Ilyinskii PO; Roy CJ; O'Neil CP; Browning EA; Pittet LA; Altreuter DH; Alexis F; Tonti E; Shi J; Basto PA; Iannacone M; Radovic-Moreno AF; Langer RS; Farokhzad OC; von Andrian UH; Johnston LP; Kishimoto TK
    Vaccine; 2014 May; 32(24):2882-95. PubMed ID: 24593999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rational Design of PLGA Nanoparticle Vaccine Delivery Systems To Improve Immune Responses.
    Gu P; Wusiman A; Zhang Y; Liu Z; Bo R; Hu Y; Liu J; Wang D
    Mol Pharm; 2019 Dec; 16(12):5000-5012. PubMed ID: 31621331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.